CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home »

ONCOLOGY. Vol. 13 No. 1
 

Komen Foundation Receives Grant to Develop New Breast Imaging Technology

January 1, 1999

The Susan G. Komen Breast Cancer Foundation, a pioneer in the funding of research for breast cancer, announced at its 1998 National Grant Conference that the Joseph Drown Foundation has awarded the Komen Foundation a matching grant of $500,000 for the establishment of a new competitive grant category, Breast Cancer Imaging Technology. Imaging technology researchers will now be given the opportunity and priority needed to potentially save lives.

“Until researchers find the cause and ultimately the cure for breast cancer, early detection and proper treatment are the best defense against the disease,” said Norman C. Obrow, president of the Joseph Drown Foundation. The foundation, based in Los Angeles, was formed in 1953 to provide an organized means for its founder, Joseph Warford Drown, to make charitable gifts during his lifetime and to have the foundation continue making grants upon his death.

“Although mammography is an important tool in the diagnosis of breast disease, the advances that are now possible in screening and diagnostic imaging are exciting,” Obrow said. “We are proud to provide the Komen Foundation the opportunity to fund the development of these new technologies.”

Although mammography is the standard for breast cancer screening, it is a method that has not yet been perfected. Experts estimate that approximately 10% of cancers are missed by mammography.

“In the late 1980s, most companies and institutions thought that imaging of the breast with MRI was a waste of resources. Komen believed in our research and funded the first successful development of MRI technology for detection of breast cancer,” said Steven Harms, md, current Komen grant recipient and professor and chief of VA Radiology at the Arkansas Cancer Research Center, University of Arkansas.

Areas of Research to Be Funded

Through this gift from the Drown Foundation, the Komen Foundation will be able to fund additional research conducted in, but not limited to, the following areas of screening and diagnostic imaging: digital mammography using telemedicine, magnetic resonance imaging (MRI), positron emission tomography (PET), and ultrasound. The grant funding, which will be matched by the Komen Foundation, will provide the foundation with the means necessary to continue funding innovative new programs.

“More than a decade ago, at a time when no other organization was funding research specifically for breast cancer, the Komen Foundation had the foresight to recognize that funding for this research was paramount to the survival of the women who suffer from the disease,” said Susan Braun, president and chief executive officer of the Susan G. Komen Breast Cancer Foundation. “Through its support, the Drown Foundation has enabled the Komen Foundation to become a leader in funding important new technologies and to make further strides in the pursuit of our mission—eradicating breast cancer as a life-threatening disease.”

The foundation will offer to researchers grants of up to $200,000 over a 2-year period for breast cancer imaging technology studies. It will be open to all not-for-profit and educational institutions and organizations in the United States and abroad. Research projects will be selected for funding through the Komen Foundation’s blinded, peer-review process, which is recognized by the National Cancer Institute as exemplary.

1998 National Grant Conference

The announcement of the Breast Cancer Imaging Technology grant category came at the Komen Foundation’s 1998 National Grant Conference, which brought together current Komen grant recipients and experts in the field of breast cancer to present their latest research and outreach projects.

Each year, the Komen National Grants Conference presents a unique opportunity for researchers to “come out of the lab” and hear from the patients, survivors, and doctors who face this disease every day. This year’s conference featured 51 presentations from Komen grant recipients representing 15 states and 3 countries, as well as 40 different institutions and organizations.

“Designed by breast cancer advocates, the grant conference brings together all of those fighting the disease and provides a forum for discussion and sharing of ideas,” said Elda Railey, director of grants for the Susan G. Komen Breast Cancer Foundation. “The presentations are given in easy-to-understand, lay terms so that those who support the research and those who will eventually be affected by the research can truly appreciate the work that is being done.”

Other presenters at the conference included: Gil Friedel, MD, Markey Cancer Center, University of Kentucky, Lexington; M. Anne Blackwood, MD, University of Pennsylvania, Philadelphia; Anna H. Wu, PhD, University of Southern California, Los Angeles; and Patricia A.Ganz, MD, University of California at Los Angeles.

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
IMAGE IQ

Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
James B. Yu, MD1 , May 17, 2013

A 70-year-old man with a history of localized prostate cancer treated with whole-pelvis radiation therapy with a boost to the prostate, in conjunction with androgen deprivation therapy 7 years prior, presented with lower back pain. A bone scan revealed an area of activity in the sacrum. What is the most likely diagnosis?

More Image IQs 

 
FROM PHYSICIANS PRACTICE
Primary Care Can't Thrive Without Nurse Practitioners
Courtney H. Lyder, ND,  May 17, 2013
With a projected shortfall of primary-care physicians, it's time for alternate solutions to patient care. Nurse practitioners are one logical remedy.
VWhat Physicians Can Learn from the Allscripts EHR Lawsuit
Marisa Torrieri,  May 16, 2013
Lawsuit prompts question: What should physicians do to ensure they end up with a great EHR instead of buyer’s remorse?
Eight Ways ICD-9 Will Still Matter to Medical Practices
Brenda Edwards, CPC,  May 15, 2013
What should your medical practice do with your ICD-9-CM book after October 1, 2014? Keep it.
Seven Ways Technology Can Speed Up Patient Collections
Cheyenne Brinson,  May 15, 2013
Failing to adopt widely available billing and collections technology can cost medical practices big. Here's how to do it right.
Four Reasons Private Medical Practice is Becoming Extinct
Carol Stryker,  May 15, 2013
It’s becoming increasingly difficult for private medical practices to thrive. Here’s what’s driving the trend toward consolidation.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Skin Lesions
  • Colorectal Lesions
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Slide Show: Squamous Cell Carcinoma of the Head and Neck
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • ONS: Understanding Spirituality and How It Can Be Used to Help Patients
  • Colorectal Lesions
  • New AUA Guidelines for Prostate Cancer Screening
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • Genomics Studies Identify Testicular Cancer Risk Variants
  • Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
  • FDA Approves Erlotinib (Tarceva) as First-Line Lung Cancer Therapy for Certain Patients
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • “This Is My Last Day on Earth”
  • Financial Toxicity, Part II: How Can We Help With the Burden of Treatment-Related Costs?
  • Patient Quality of Life Endpoints in Oncology Trials, Part II
  • Who's Coding Whom?
  • “How Do I Say This Nicely? Your Oncologist Wasn't Following Guidelines”
  • Study: Cholesterol Drugs Reduced Risk of Prostate Cancer Death
  • “This Is My Last Day on Earth”
  • ONS: Safe Handling of Chemotherapy
  • Financial Toxicity, Part II: How Can We Help With the Burden of Treatment-Related Costs?
  • Conflicts of Interest in Medicine: What About Ties to Payers?
Click here to subscribe to our newsletter



CancerNetwork on Facebook

CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy